Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GLIATECH ADCON-L ANTI-ADHESION GEL APPROVABLE FOR REDUCING PERIDURAL FIBROSIS AFTER LUMBAR SURGERY, FDA PANEL SAYS; DATA DO NOT SUPPORT PAIN RELIEF CLAIM

This article was originally published in The Gray Sheet

Executive Summary

Gliatech's Adcon-L anti-adhesion gel should include in final labeling a statement explaining that no data exist to support long-term pain relief, FDA's Orthopedic and Rehabilitation Devices Advisory Panel recommended at a Dec. 12 meeting. The suggestion was one of several conditions for FDA approval of a premarket approval application for Adcon-L in reducing peridural fibrosis and adhesions following single-level (L4-L5 or L5-S1), posterior lumbar laminectomy or discectomy.

You may also be interested in...



Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.

Manpower Not Materials Could Hold German COVID-19 Testing Back

Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.

Commission Regulatory Advice For COVID-19 Medtech Sector Entrants Amid Counterfeit Concerns

A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.

UsernamePublicRestriction

Register

MT009283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel